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Abstract 
 
Central nervous system (CNS) hemangioblastoma is the most common manifestation of von 
Hippel-Lindau (VHL) disease. It is found in 70-80% of VHL patients. Hemangioblastoma is a 
rare form of benign vascular tumor of the CNS, accounting for 2.0% of CNS tumors. It can 
occur sporadically or as a familial syndrome. CNS hemangioblastomas are typically located 
in the posterior fossa and the spinal cord. VHL patients usually develop a CNS 
hemangioblastoma at an early age. Therefore, they require a special routine for diagnosis, 
treatment and follow-up. The surgical management of symptomatic tumors depend on 
many factors such as symptom, location, multiplicity, and progression of the tumor.  The 
management of asymptomatic tumors in VHL patients are controversial since CNS 
hemangioblastomas grow with intermittent quiescent and rapid-growth phases. 
Preoperative embolization of large solid hemangioblastomas prevents perioperative 
hemorrhage but is not necessary in every case. Radiotherapy should be reserved for 
inoperable tumors. Because of complexities of VHL, a better understanding of the 
pathological and clinical features of hemangioblastoma in VHL is essential for its proper 
management. Copyright: The Authors. 
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Introduction 
 
Von Hippel-Lindau (VHL) disease is 
inherited in an autosomal dominant 
pattern and characterized by the 
development of hemangioblastomas (HBs) 
of the central nervous system (CNS) and 
retina, renal cell carcinoma, 
pheochromocytoma, pancreatic and 
endolymphatic sac tumors. CNS HB is the 
most common VHL-associated lesion, and 
it is found in 70-80% of VHL patients. HB 
is a WHO grade 1 tumor, composed of 
stromal cells and abundant capillaries. Its 
cytogenesis remains uncertain, but 
recently it was suggested that HB 
originates from embryonic hemangioblast. 
The neurologic morbidity and mortality 
depend on HB’s location and multiplicity. 
Because of complexities of VHL, a deep 
understanding of clinical and pathological 
features of HB in VHL is essential (1). 
 
Histopathology and molecular markers 
 
HBs are characterized histologically by two 
main components, large vacuolated stromal 
cells, and a rich capillary network 
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composed of vascular endothelia and 
pericytes. The stromal cells represent the 
neoplastic component of the tumor, but the 
histogenesis remains uncertain. It has been 
suggested that the stromal cells are derived 
from hemangioblast progenitor cells (2, 3) 
and that the vascular cells represent 
reactive angiogenesis (4). The nuclei of the 
stromal cells vary in size with occasional 
atypical and hyperchromatic nuclei. Their 
most striking morphological feature is 
numerous lipid-containing vacuoles, 
characterizing the typical clear cell 
morphology. HB histologically mimics the 
clear cell type of renal cell carcinoma, but 
differential diagnosis can be made. Renal 
cell carcinoma commonly stains for 
markers including cytokeratin, EMA and 
pan-epithelial antigen, whereas HB does 
not stain for these markers.  
 
In HB, the stromal cells and capillary 
endothelial cells significantly differ in their 
antigen expressing patterns. Stromal cells 
are commonly positive for neuron-specific 
enolase, neural cell-adhesion molecule 
(CD56), ezrin and vimentin (3). The 
capillary endothelial cells are commonly 
positive for CD 34 and CD 31(PECAM) (4). 
The stromal cells express high levels of 
epidermal growth factor receptor (EGFR), 
but the EGFR gene is not amplified (5). A 
subpopulation of the stromal cells also 
express transforming growth factor alpha 
(TGF-α), an EGFR ligand, which may 
suggest an autocrine TGF-α-EGFR loop (6). 
Vascular endothelial growth factor (VEGF) 
is highly expressed in stromal cells 
corresponding to endothelial expression of 
its receptors VEGFR-1 and -2 (7) and 
endothelial receptor Tie-1 (8). In addition to 
VEGF, erythropoietin and hypoxia 
inducible factor 2 alpha (HIF2-α) are highly 
expressed in the stromal cells (9, 10). 
 
Molecular mechanisms 
 
The VHL gene was isolated by positional 
cloning at chromosome 3p25-26 and 
encodes a protein of 213 amino acids 
corresponding to a coding sequence of 639 
nucleotides (11). The predicted protein 
contained an acidic pentameric repeat. The 
VHL gene has the characteristics of a 
classic tumor suppressor gene; i.e., loss of 
the wild type allele in CNS HB patients with 
VHL, and somatic mutations in sporadic 
CNS HB with a loss of heterozygosity (12-
14). The VHL gene is expressed in a variety 
of tissues, in particular epithelial cells of 
the skin, the gastrointestinal, respiratory 
and urogenital tracts, and the endocrine 
and exocrine organs (14, 15 16). In the 
CNS, immunoreactivity for VHL protein is 
prominent in neurons, including Purkinje 
cells of the cerebellum (17, 18). Inactivation 
of the VHL gene in affected VHL family 
members is responsible for their genetic 
susceptibility to hemangioblastoma. The 
mechanism by which VHL protein causes 
neoplastic transformation has remained 
unclear.  
 
The VHL protein binds  to elongins B and 
C, which activates transcription elongation 
by RNA polymerase H, and  inhibits elongin 
(S HI) transcriptional activity (19), 
suggesting that the VHL protein may play 
an important role in the transcriptional 
regulatory network that controls 
tumorigenesis. The wild-type VHL protein 
regulates the expression of many hypoxia-
induced genes such as vascular endothelial 
growth factor (Figure 1). The VHL protein 
inhibits the cellular expression of vascular 
endothelial growth factor, platelet-derived 
growth factor, and glucose transporter 
GLUT1 in hypoxic condition, but not in 
normoxic condition (19, 20). The VHL 
protein regulates the mRNA stability of 
these genes at the posttranscriptional level 
by interacting with elongins B and C (21).  
 
Germ line or sporadic mutations of the VHL 
gene are spread all over its three exons. 
Missense mutations are most common. 
Non-sense mutations, micro 
deletions/insertions, splice site mutations 
and large deletions are also found (22, 23). 
VHL gene mutations are also common in 
sporadic hemangioblastomas (13).  
 
 
Phenotypes of VHL are based on the 
absence (type 1) or presence (type 2) of 
pheochromocytoma. VHL type 2 is 
subdivided into three categories: type 2A, 
type 2B and type 2C. Type 2A VHL has 
pheochromocytoma with CNS HB, but not 
with RCC. Type 2B exhibits 
pheochromocytoma, renal cell carcinoma 
and CNS HBs. A recent notion is that type 
2C disease has only pheochromocytoma, 
with no other disease (24, 25) (Table 1).  
   Kanno et al.                                                                                                                   Hemangioblastoma and VHL 
                                                                                
JKCVHL 2014; 1(4):46-55 http://jkcvhl.com  48 
 
 
 
 
 
       
Figure 1. The interaction of VHL protein with HIF and other proteins including elongin B, elongin C 
and CUL2. A mutated VHL stabilizes HIF and leads to the up-regulation of many pro-angiogenic 
factors including GLUT-I, VEGF, PDGF-β, erythropoietin and TGF-α. A wild type VHL degrades HIF 
through ubiquitin-mediated pathway. 
 
 
Clinical features 
 
CNS HB is a relatively rare brain tumor, 
accounting for 2.0% of primary brain 
tumors (26).  VHL patients often have 
multiple HBs at various sites. Twenty-five 
to 30% of CNS HBs are associated with 
VHL, with 70-75% of them being sporadic. 
In VHL, 50 - 60 % of the HBs are located in 
the cerebellum, 40-50% in the spinal cord, 
10 - 20 % in the brain stem, and 2 - 4% in 
the pituitary stalk, whereas sporadic HBs 
occur predominantly in the cerebellum. 
CNS hemangioblastoma is the earliest or 
the second earliest manifestation, and the 
onset age ranges from 7 to 73 years, with 
the mean being 29 years (26, 27, 28). Signs 
and symptoms vary based on the 
anatomical tumor location, associated 
edema and cyst, and tumor size. Tumors 
that become symptomatic and require 
resection usually grow faster than 
asymptomatic ones (1). Patients with 
cerebellar HBs can present with symptoms 
owing to cerebellar impairment and 
increased intracranial pressure. These 
include: gait ataxia (64%), dysmetria (64%), 
headaches (12%), diplopia (8%), vertigo 
(8%), and emesis (8%). Patients with spinal 
HBs can present with symptoms associated 
with radiculopathy and myelopathy: 
hypesthesia (83%), weakness (65%), gait 
ataxia (65%), hyper-reflexia (52%), pain 
(17%), and incontinence (14%). Patients 
with brain stem HBs can display symptoms 
mainly due to both lower cranial nerve 
impairment and high intracranial pressure: 
hypesthesia (55%), gait ataxia (22%), 
dysphagia (22%), hyper-reflexia (22%), 
headaches (11%), and dysmetria (11%) 
(29). In rare cases, CNS HBs present by 
intra-parenchymal or subarachnoid 
hemorrhage (29). Approximately 5% of 
patients develop polyglobulia, which can be 
cured by removing the solid tumor mass 
(28, 30). Most symptoms do not arise from 
the solid tumor itself but from the 
associated rapidly growing cyst or syrinx 
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           Table 1. Clinical classifications and manifestations of VHL disease 
  Clinical manifestations  
 CNS HB Renal Cell carcinoma Pheochromocytoma 
VHL type 1         + + - 
VHL type 2A + - + 
VHL type 2B       + + + 
VHL type 2C       - - + 
 
 
(29). Therefore, symptoms can occasionally 
develop rapidly; however, usually they 
develop slowly (29, 31-33). Growth patterns 
vary and are categorized as saltatory (70-75 
% of growing tumors), linear (5-7%) or 
exponential (20-25%). Many tumors remain 
same in size for several years (32). VHL 
patients are found to have a mean of 8.5 
tumors/patient (range, 1 to 33 
tumors/patients) at initial evaluation. 
Mean tumor development is 0.4 new 
tumors/year and is correlated with age, 
with more frequent development in the 
younger patients (31).  Performance status 
(PS) of VHL patients with CNS HBs has 
been assessed according to the Eastern 
Cooperative Oncology Group performance 
status (EOCG PS; 4). This study results 
revealed that most patients have a low 
ECOG PS score (PS=0, 1). The mean ECOG 
PS of patients with a single CNS HB was 
significantly lower than that of patients 
with multiple CNS HBs (27). Patients 
bearing HBs often show polycythemia 
owing to erythropoietin secreted from HB 
cells. In familial cases, genetic testing can 
detect VHL gene mutations in peripheral 
blood or tumor tissue (22). In sporadic HB, 
such mutations can be detected only in 
tumor tissues (13).  
 
Neuroimaging  
 
HBs are most often visualized by contrast-
enhanced T1-weighted MR-imaging (Figure 
2). In post-contrast images the tumor 
tissue appears as a homogenous bright 
contrast-enhanced mass that clearly 
stands out from the surrounding tissue. 
T2-weighted or flair MR-imaging allows 
excellent quantification of edema and peri-
tumoral cysts, which appear as high-signal 
areas. Cyst walls of HBs are not usually 
enhanced on MRI. Angiography can be 
used to highlight the tumor staining, 
arteriovenous shunting, and early draining 
veins associated with these tumors prior to 
resection. Angiography is also performed 
for intended preoperative embolization in 
the case of large solid HBs. CT scan has 
been replaced by MRI (34). 
 
Clinical diagnostic criteria for VHL 
 
VHL is diagnosed according to clinical 
diagnostic criteria (29). In the presence of a 
positive family history, VHL can be 
diagnosed clinically in a patient with at 
least one typical VHL tumor, such as 
retinal or CNS HB, renal cell carcinoma, 
pheochromocytoma or pancreatic tumor. 
Endolymphatic sac tumors and multiple 
pancreatic cysts suggest a positive carrier. 
In contrast, in patients with a negative 
family history of VHL-associated tumors, 
diagnosis of VHL can be made when such 
patients exhibit two or more CNS HBs or a 
single HB in association with a visceral 
tumor such as renal cell carcinoma, 
pheochromocytoma or pancreatic tumor 
(29).  
 
Management and follow-up  
 
Therapeutic strategy  
 
The therapeutic strategy for each CNS HB 
in VHL has to be discussed individually 
with respect to the tumor location, tumor 
size or associated cysts, as well as 
symptoms and general condition of the 
patient, because most VHL patients will 
develop numerous HBs growing at different 
rates and at several locations (Figure 3). In 
addition, a past therapeutic history of each 
VHL patient should be taken into account. 
Although the appropriate treatment 
strategies for CNS HBs are still a matter of 
debate, there is a general consensus that 
the symptomatic tumors should be treated 
(34-38). Since CNS HBs do not grow 
continuously at the same rate but with 
intermittent quiescent and rapid-growth 
phases, therapeutic strategies for 
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Figure 2. Contrast-enhanced T1 weighted MRI of CNS HBs in VHL. Left, multi-cerebellar HBs; right, 
lumbar spinal cord HB with syrinx. 
 
 
asymptomatic tumors in VHL patients are 
controversial. Asymptomatic tumors, which 
are stable in MRI screening, are 
recommended to be followed 
radiographically. In the case of 
asymptomatic but progressive tumors, 
treatment strategies slightly differ in the 
literature. Some reports recommend early 
surgery (39) since preoperative neurological 
symptoms are usually reversible, and 
surgical resection can be usually performed 
with low morbidity. For spinal cord HBs, 
the surgical outcome of the tumor volume 
less than 500mm3 was better than that 
were larger than 500mm3. If the tumor 
volume exceeds 500mm3 during follow-up 
by MRI, surgical treatment might be 
considered. 
 
Preoperative management  
 
As to preoperative management for CNS 
HBs, preoperative embolization can be 
helpful in the case of large solid tumors to 
prevent intraoperative hemorrhage. There 
is no general consensus on preoperative 
embolization since this procedure is 
occasionally associated with side effects 
such as swelling, hemorrhage, and 
infarction. The time span between 
embolization and an operation should not 
exceed three days, since peri-focal swelling 
can cause enhanced unnecessary risks (1, 
34).  
 
Surgical treatment  
 
Surgical treatment is usually the first 
choice therapy for CNS HBs, and its final 
goal is the complete resection of all tumor 
components. Since most VHL patients bear 
multiple CNS HBs and undergo multiple 
surgeries causing deterioration of 
performance status (27), at the removal of 
symptomatic tumors any small 
asymptomatic tumors in the same 
anatomical location should be removed 
simultaneously if they can be found. The 
cystic wall without contrast enhancement 
may be left untreated since the cyst wall 
does not include the tumor cells. The cystic 
wall usually consists of reactive gliosis 
without an epithelial lining (38). 
Occasionally, cysts associated with tumors 
will refill again in the case of incomplete 
resection of the solid tumor (40). Since 
hemangioblastomas are highly vascular 
tumors, it is not recommended to cut the 
tumor into pieces since debulking of the 
tumor can cause extensive bleeding. 
Without losing sight of the tumor margin, 
resection must be carried out with careful 
dissection, and cutting and coagulation of 
each feeding vessel must be done. It is 
therefore necessary to consequently dissect 
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Figure 3. Clinical management of hemangioblastomas. 
 
 
the plane between the tumor capsule and 
the surrounding tissue. In many cases the 
cyst is much bigger than the solid part and 
is causative of progressive neurological 
symptoms (37, 38). The solid tumor itself 
can be distinguished from the surrounding 
brain tissue due to its reddish or orange 
color and can usually be removed 
completely. However, distinction from the 
surrounding vessels is occasionally 
difficult. In this case, intraoperative 
indocyanine green (ICG) video angiography 
and fluorescent visualization with 5-ALA 
facilitate to visualize tumors themselves 
and/or the surrounding vessels (41, 42). 
Doppler flow sonography with a contrast-
enhancing agent can be also useful, since it 
is a sensitive intraoperative tool to guide 
the surgical approach and resection (43, 
44).  
 
Motor-evoked potentials for spinal cord 
HBs should be applied in the case of 
surgery of spinal cord HBs (38). If the 
spinal cord HB is not visible on the surface 
of the spinal cord, enlarged arterialized 
veins can be helpful for finding the tumor. 
These enlarged arterialized veins except for 
those penetrating the tumor should be 
preserved to avoid swelling and 
hemorrhage from the tumor. Even if a 
dorsal fascicle is involved in the tumor, it 
can usually be removed with no 
neurological deficit or only slight 
disturbance of deep sensation (38).  
Radiotherapy  
 
Stereotactic radiosurgery for HBs results in 
a high local control rate in CNS HBs with 
acceptable levels of radiation-induced 
complications (45). Principally, stereotactic 
radiosurgery can be used for surgically 
inaccessible or multiple cranial and spinal 
tumors (46). More recently, fractionated 
external beam radiotherapy (EBRT; 47) and 
infratentorial craniospinal radiation 
therapy (ICSRT; 48) have been investigated 
for use against CNS HBs, and favorable 
outcomes were reported.  
 
Follow-up of CNS HBs in VHL patients  
 
VHL patients with CNS HBs should 
undergo MRI of the brain and spinal cord 
at least once a year. VHL patients above 10 
years old, who do not display CNS HBs, 
should undergo MRI screening of their 
whole neuro-axis every two years. An 
annual ophthalmoscopy should be 
performed to screen for retinal HBs. A 
yearly MRI of the abdomen is 
recommended to screen for renal cell 
carcinoma, pancreatic lesions, and 
pheochromocytoma (29, 34). In addition, a 
yearly abdominal ultrasound with triennial 
computed tomography (CT) imaging for 
renal cell carcinoma, a yearly audiometry 
for endolymphatic tumor, and 
pheochromocytoma investigation by urine 
analysis (metanephrine - VMA) are 
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recommended. Based upon clinical 
indication these follow-up modalities 
should be advanced or extended (49). 
 
Conclusion 
 
The neurologic morbidity and mortality 
depend on the location and multiplicity of 
CNS HBs. Because of the complexities of 
VHL, a deep understanding of pathological 
and clinical features of HB in VHL is 
essential, and the management strategies 
should be tailored to the needs of the 
individual patients.  
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